Sign In
Buy WINT
$0.0140
+0.0004 (+2.94%)
At Close: Jun 03, 2026
Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product
08:00am, Thursday, 20'th Mar 2025
WARRINGTON, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating
Windtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company's Oncology Pipeline
08:00am, Wednesday, 15'th Jan 2025
The Company's oncology aPKCi inhibitor is a novel, first in class drug candidate The Company's oncology aPKCi inhibitor is a novel, first in class drug candidate
WINT and Ferguson announce strategic collaboration to elevate water management and leak mitigation for real estate and construction
09:00am, Tuesday, 14'th Jan 2025
Industry leaders deliver comprehensive distribution of AI-based water management, protection and risk mitigation solutions throughout the U.S. NEW YORK, Jan. 14, 2025 /PRNewswire/ -- WINT Water Intell
Windtree Announces the Addition of Leanne Kelly to Its Board of Directors
08:00am, Monday, 13'th Jan 2025
WARRINGTON, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage
Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia
08:00am, Monday, 09'th Dec 2024
WARRINGTON, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage
WARRINGTON, Pa., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage
Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates
04:05pm, Wednesday, 27'th Nov 2024
WARRINGTON, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stag
Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the World
08:00am, Wednesday, 23'rd Oct 2024
WARRINGTON, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage
Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan
08:15am, Thursday, 17'th Oct 2024
WARRINGTON, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage
Istaroxime treatment significantly improved systolic blood pressure as well as cardiac output and renal function without increasing heart rate or clinically significant arrythmias
Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET
04:05pm, Thursday, 26'th Sep 2024
New Istaroxime Phase 2b clinical results to be presented by Windtree and top cardiology expert Review of cardiogenic shock and other programs, including Windtree's strategy and planned near-term miles
Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock
08:15am, Wednesday, 25'th Sep 2024
Istaroxime significantly improved primary endpoint of the systolic blood pressure profile over six hours and showed significant improvements in many secondary endpoint assessments
Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business Updates
04:05pm, Tuesday, 20'th Aug 2024
WARRINGTON, Pa., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stag
Windtree Announces New Additions and Changes to Its Board of Directors
04:05pm, Wednesday, 14'th Aug 2024
WARRINGTON, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage
Why Is Windtree Therapeutics (WINT) Stock Up 116% Today?
08:01am, Friday, 26'th Jul 2024
Windtree Therapeutics (NASDAQ: WINT ) stock is rocketing higher on Friday after the biotechnology company provided an update on its clinical trial of istaroxime. Windtree Therapeutics notes that it i
